Gilead Expands Licensing for Once-Yearly HIV Prevention Drug — Gilead Sciences, Inc.

Event summary

Gilead expanded six royalty-free voluntary licensing agreements for lenacapavir to include investigational once-yearly HIV prevention as PrEP.
The agreements cover 120 high-incidence, low- and lower-middle-income countries.
PURPOSE 365 Phase 3 trial is ongoing to evaluate the pharmacokinetics, safety, and tolerability of once-yearly lenacapavir.
Twice-yearly lenacapavir demonstrated unprecedented efficacy in Phase 3 PURPOSE 1 and PURPOSE 2 trials.
Gilead aims to enable broad, sustainable access to multiple generic long-acting HIV prevention options.

The big picture

Gilead’s move to expand licensing agreements for once-yearly lenacapavir underscores its commitment to broadening access to HIV prevention in resource-limited settings. The strategy aligns with global health goals to reduce new HIV infections, addressing significant gaps in PrEP uptake. With the PURPOSE 365 trial ongoing, the success of this approach hinges on regulatory approval and effective implementation in high-incidence countries.

What we're watching

Regulatory Approval: Whether the PURPOSE 365 trial results will support regulatory approval for once-yearly lenacapavir.
Market Adoption: The pace at which once-yearly lenacapavir can be integrated into healthcare systems in high-incidence regions.
Competitive Dynamics: How Gilead’s expanded access strategy will position lenacapavir against existing and emerging HIV prevention options.